Moderna said it was developing a single-dose Corona vaccine in combination with the flu vaccine. That vaccine is intended to fight the respiratory virus (RSV) and can be used as an annual dose.
Stephane Bancel, Chief Executive Officer (CEO) of Moderna considers this is a great opportunity.
“We believe this is a huge opportunity that lies ahead of us if we can bring to market a highly efficacy pan-respiratory annual,”Bancel said.
This new combined vaccine is the furthest experiment they have developed regarding Covid-19. Quoted from detikcom, clinical trials of this combination vaccine are likely to start over the next 6-12 months.
Moderna also provided an update on an ongoing mid-stage trial testing its Covid-19 vaccine on children aged 6 months to 11 years. The trial is known to examine 50 microgram doses of the vaccine made in 4,000 children.
Moderna’s Covid-19 vaccine is authorized for emergency use in people over 18 in the US. The dose given is two doses of 100 micrograms. It is known, earlier this year, the US granted permission to use the Covid-19 vaccine made by Pfizer-BioNTech for adolescents aged 12 to 15 years.